Hyperthyroidism is a set of disorders that involve excess synthesis and secretion of thyroid hormones by the thyroid gland, which leads to thyrotoxicosis. The most common forms of hyperthyroidism include diffuse toxic goiter (Graves’ disease), toxic multinodular goiter (Plummer’s disease), and a solitary toxic adenoma. The most reliable screening measure of thyroid function is the thyroid-stimulating hormone (TSH) level. Options for treatment of hyperthyroidism include antithyroid drugs, radioactive iodine therapy (the preferred treatment of hyperthyroidism among US thyroid specialists), or thyroidectomy. Massive thyroid enlargement with compressive symptoms, a suspicious nodule, Graves’ orbitopathy, and patient preference are indications for surgical treatment of thyrotoxicosis.
- Graves’ disease
- Thyroid-stimulating hormone
- Anti-TSH receptor Antibodies
- Toxic nodular goiter
- Plummer’s disease
- Antithyroid drugs
- Radioactive iodine
This is a preview of subscription content, access via your institution.
Tax calculation will be finalised at checkout
Purchases are for personal use onlyLearn about institutional subscriptions
Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T-4 and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87(2):489–99.
Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343–421.
Morshed SA, Latif R, Davies TF. Delineating the autoimmune mechanisms in Graves’ disease. Immunol Res. 2012;54(1–3):191–203.
Smith TJ, Hegedüs L. Graves’ disease. N Engl J Med. 2016;375(16):1552–65.
McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine. 2012;42(2):252–65.
McLeod DS, Caturegli P, Cooper DS, Matos PG, Hutfless S. Variation in rates of autoimmune thyroid disease by race/ethnicity in US military personnel. JAMA. 2014;311(15):1563–5.
Antonelli A, Ferrari SM, Ragusa F, et al. Graves’ disease: epidemiology, genetic and environmental risk factors and viruses. Best Pract Res Clin Endocrinol Metab. 2020;34(1):101387.
Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev. 2000;21(2):168–99.
Kubota S, Gunji K, Stolarski C, Kennerdell JS, Wall J. Reevaluation of the prevalences of serum autoantibodies reactive with “64-kd eye muscle proteins” in patients with thyroid-associated ophthalmopathy. Thyroid. 1998;8(2):175–9.
Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J. 2016;5(1):9–26.
Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab. 2012;97(12):4549–58.
Wartofsky L, Glinoer D, Solomon B, et al. Differences and similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan, and the United States. Thyroid. 1991;1(2):129–35.
Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European thyroid association guideline for the management of Graves’ hyperthyroidism. Eur Thyroid J. 2018;7(4):167–86.
Moon JH, Yi KH. The diagnosis and management of hyperthyroidism in Korea: consensus report of the Korean Thyroid Association. Endocrinol Metab (Seoul). 2013;28(4):275–9.
In H, Pearce EN, Wong AK, Burgess JF, McAneny DB, Rosen JE. Treatment options for Graves’ disease: a cost-effectiveness analysis. J Am Coll Surg. 2009;209(2):170–9.
Masiello E, Veronesi G, Gallo D, et al. Antithyroid drug treatment for Graves’ disease: baseline predictive models of relapse after treatment for a patient-tailored management. J Endocrinol Investig. 2018;41(12):1425–32.
Yoshihara A, Noh J, Yamaguchi T, et al. Treatment of Graves’ disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab. 2012;97(7):2396–403.
Andersen SL, Olsen J, Wu CS, Laurberg P. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. J Clin Endocrinol Metab. 2013;98(11):4373–81.
Hertz S, Roberts A. Radioactive iodine in the study of thyroid physiology. The use of radioactive iodine therapy in hyperthyroidism. J Am Med Assoc. 1946;131:81–6.
Bogazzi F, Giovannetti C, Fessehatsion R, et al. Impact of lithium on efficacy of radioactive iodine therapy for Graves’ disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal. J Clin Endocrinol Metab. 2012;95(1):201–8.
Laurberg P, Wallin G, Tallstedt L, et al. TSH-receptor autoimmunity in Graves’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol. 2008;158(1):69–75.
Ponto KA, Zang S, Kahaly GJ. The tale of radioiodine and Graves’ orbitopathy. Thyroid. 2010;20(7):785–93.
Bhargav PRK, Sabaretnam M, Kumar SC, Zwalitha S, Devi NV. Regression of ophthalmopathic exophthalmos in Graves’ disease after total thyroidectomy: a prospective study of a surgical series. Indian J Surg. 2017;79(6):521–6.
Lorenz K, Raffaeli M, Barczyński M, Lorente-Poch L, Sancho J. Volume, outcomes, and quality standards in thyroid surgery: an evidence-based analysis-European Society of Endocrine Surgeons (ESES) positional statement. Langenbeck’s Arch Surg. 2020;405(4):401–25.
Yilmaz Y, Kamer KE, Ureyen O, Sari E, Acar T, Karahalli O. The effect of preoperative Lugol’s iodine on intraoperative bleeding in patients with hyperthyroidism. Ann Med Surg (Lond). 2016;9:53–7.
Whalen G, Sullivan M, Maranda L, Quinlan R, Larkin A. Randomized trial of a short course of preoperative potassium iodide in patients undergoing thyroidectomy for Graves’ disease. Am J Surg. 2017;213(4):805–9.
Erbil Y, Ozluk Y, Giriş M, et al. Effect of Lugol’s solution on thyroid gland blood flow and microvessel density in the patients with Graves’ disease. J Clin Endocrinol Metab. 2007;92(6):2182–9.
Mercier F, Bonal M, Fanget F, et al. Does surgery without Lugol’s solution pretreatment for graves’ disease increase surgical morbidity? World J Surg. 2018;42(7):2123–6.
Jörtsö E, Lennquist S, Lundström B, Norrby K, Smeds S. The influence of remnant size, antithyroid antibodies, thyroid morphology, and lymphocytic infiltration on thyroid function after subtotal resection for hyperthyroidism. World J Surg. 1987;11(3):365–71.
Alsnea O, Clark OH. Treatment of Graves’ disease: the advantages of surgery. Endocrinol Metab Clin N Am. 2000;29(2):321–37.
Barczyński M, Konturek A, Hubalewska-Dydejczyk A, Gołkowski F, Nowak W. Randomized clinical trial of bilateral subtotal thyroidectomy versus total thyroidectomy for Graves’ disease with a 5-year follow-up. Br J Surg. 2012;99(4):515–22.
Maurer E, Maschuw K, Reuss A, et al. Total versus near-total thyroidectomy in Graves’ disease: results of the randomized controlled multicenter TONIG-trial. Ann Surg. 2019;270(5):755–61.
Liu ZW, Masterson L, Fish B, Jani P, Chatterjee K. Thyroid surgery for Graves’ disease and Graves’ ophthalmopathy. Cochrane Database Syst Rev. 2015;(11):CD010576.
Bobanga ID, McHenry CR. Treatment of patients with Graves’ disease and the appropriate extent of thyroidectomy. Best Pract Res Clin Endocrinol Metab. 2019;33(4):101319.
Berghout A, Wiersinga WM, Smits NJ, Touber JL. Interrelationships between age, thyroid volume, thyroid nodularity, and thyroid function in patients with sporadic nontoxic goiter. Am J Med. 1990;89(5):602–8.
Gozu HI, Lublinghoff J, Bircan R, Paschke R. Genetics and phenomics of inherited and sporadic non-autoimmune hyperthyroidism. Mol Cell Endocrinol. 2010;322(1–2):125–34.
Siegel RD, Lee SL. Toxic nodular goiter: toxic adenoma and toxic multinodular goiter. Endocrinol Metab Clin N Am. 1998;27(1):151–68.
Krohn K, Führer D, Bayer Y, et al. Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocr Rev. 2005;26(4):504–24.
Vitti P, Rago T, Tonacchera M, Pinchera A. Toxic multinodular goiter in the elderly. J Endocrinol Invest. 2002;25(10 suppl):16–18.
Vadiveloo T, Donnan PT, Cochrane L, Leese GP. The Thyroid Epidemiology, Audit, and Research Study (TEARS): the natural history of endogenous subclinical hyperthyroidism. J Clin Endocrinol Metab. 2011;96(1):E1–8.
Rosario PW. Natural history of subclinical hyperthyroidism in elderly patients with TSH between 0.1 and 0.4 mIU/l: a prospective study. Clin Endocrinol (Oxf). 2010;72(5):685–8.
Das G, Ojewuyi TA, Baglioni P, Geen J, Premawardhana LD, Okosieme OE. Serum thyrotrophin at baseline predicts the natural course of subclinical hyperthyroidism. Clin Endocrinol. 2011;77(1):146–51.
Pearce EN. Diagnosis and management of thyrotoxicosis. BMJ. 2006;332(7554):1369–73.
Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G. High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves’ disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland. J Intern Med. 1991;229(5):415–20.
Abraham-Nordling M, Byström K, Törring O, et al. Incidence of hyperthyroidism in Sweden. Eur J Endocrinol. 2011;165(6):899–905.
Fradkin JE, Wolff J. Iodide-induced thyrotoxicosis. Medicine (Baltimore). 1983;62(1):1–20.
Nayak B, Hodak SP. Hyperthyroidism. Endocrinol Metab Clin N Am. 2007;36(3):617–56.
van Soestbergen MJ, van der Vijver JC, Graafland AD. Recurrence of hyperthyroidism in multinodular goiter after long-term drug therapy: a comparison with Graves’ disease. J Endocrinol Investig. 1992;15(11):797–800.
Azizi F, Takyar M, Madreseh E, Amouzegar A. Treatment of toxic multinodular goiter: comparison of radioiodine and long-term methimazole treatment. Thyroid. 2019;29(5):625–30. https://doi.org/10.1089/thy.2018.0397.
Huysmans DA, Hermus AR, Corstens FH, Barentsz JO, Kloppenborg PW. Large, compressive goiters treated with radioiodine. Ann Intern Med. 1994;121(10):757–62.
Nygaard B, Hegedüs L, Ulriksen P, Nielsen KG, Hansen JM. Radioiodine therapy for multinodular toxic goiter. Arch Intern Med. 1999;159(12):1364–8.
Schiavo M, Bagnara MC, Camerieri L, et al. Clinical efficacy of radioiodine therapy in multinodular toxic goiter, applying an implemented dose calculation algorithm. Endocrine. 2015;48(3):902–8.
Ríos A, Rodríguez JM, Balsalobre MD, Torregrosa NM, Tebar FJ, Parrilla P. Results of surgery for toxic multinodular goiter. Surg Today. 2005;35(11):901–6.
Schneider R, Randolph GW, Dionigi G, et al. International neural monitoring study group guideline 2018 part I: staging bilateral thyroid surgery with monitoring loss of signal. Laryngoscope. 2018;128(Suppl 3):S1–S17.
Miccoli P, Antonelli A, Iacconi P, Alberti B, Gambuzza C, Baschieri L. Prospective, randomized, double-blind study about effectiveness of levothyroxine suppressive therapy in prevention of recurrence after operation: result at the third year of follow up. Surgery. 1993;114(6):1097–101.
Agarwal G, Aggarwal V. Is total thyroidectomy the surgical procedure of choice for benign multinodular goiter? An evidence-based review. World J Surg. 2008;32(7):1313–24.
Ríos A, Rodríguez JM, Galindo PJ, Montoya MJ, Canteras M, Parrilla P. Surgical treatment of multinodular goiter in young patients. Endocrine. 2005;27(3):245–52.
Moalem J, Suh I, Duh QY. Treatment and prevention of recurrence of multinodular goiter: an evidence-based review of the literature. World J Surg. 2008;32(7):1301–12.
Vidal-Trecan GM, Stahl JE, Eckman MH. Radioiodine or surgery for toxic thyroid adenoma: dissecting in important decision. A cost-effectiveness analysis. Thyroid. 2004;14(11):933–45.
Barczyński M, Konturek A, Hubalewska-Dydejczyk A, Gołkowski F, Nowak W. Ten-year follow-up of a randomized clinical trial of total thyroidectomy versus Dunhill operation versus bilateral subtotal thyroidectomy for multinodular non-toxic goiter. World J Surg. 2018;42(2):384–92.
Cerci C, Cerci SS, Eroglu E, et al. Thyroid cancer in toxic and non-toxic multinodular goiter. J Postgrad Med. 2007;53(3):157–60.
Alexopoulou O, Beguin C, Buysschaert M, et al. Predictive factors of thyroid carcinoma in non-toxic multinodular goiter. Acta Clin Belg. 2004;59(2):84–9.
Senyurek Giles Y, Tunca F, Boztepe H, Kapran Y, Terzioglu T, Tezelman S. The risk factors for malignancy in surgically treated patients for Graves’s disease, toxic multinodular goiter, and toxic adenoma. Surgery. 2008;144(6):1028–36.
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1–133.
Editors and Affiliations
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Barczyński, M. (2021). Graves’ Disease and Toxic Nodular Goiter (Plummer’s Disease). In: Shifrin, A.L., Raffaelli, M., Randolph, G.W., Gimm, O. (eds) Endocrine Surgery Comprehensive Board Exam Guide. Springer, Cham. https://doi.org/10.1007/978-3-030-84737-1_3
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-84736-4
Online ISBN: 978-3-030-84737-1